Phase 3 trials, like OPTIMAL (erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer)[5] and IPASS (Iressa Pan Asia Study) [6], have shown clear improvements in response rates and progression free survival (PFS) with first generation TKIs in the first line setting when compared to traditional platinum based chemotherapy. Here, EGFR is linked to non-small cell lung carcinoma.